If the page does not redirect, click here
Drug cuts cardiovascular disease and lung cancer risk by reducing inflammation (CANTOS)
The IL-1? inhibitor canakinumab lowers the risk of cardiovascular disease and lung cancer risk by reducing inflammation, according to late-breaking results.